- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Geron Corporation (GERN)
Geron Corporation stock price live, this page displays NASDAQ GERN stock exchange data. View the GERN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Geron Corporation real time stock price chart below.
What Is the Geron Corporation Stock Price Today?
The Geron Corporation stock price today is 1.1550.
What Is the Stock Symbol for Geron Corporation?
The stock symbol for Geron Corporation is ""GERN.""
What Stock Exchange Does Geron Corporation Trade On?
Geron Corporation is listed and trades on the NASDAQ stock exchange.
Is Geron Corporation a Good Stock to Buy?
Determining whether Geron Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GERN quote. (ISIN: US3741631036)
What Is the Geron Corporation Stock Price Today?
The Geron Corporation stock price today is 1.1550.
What Is the Stock Symbol for Geron Corporation?
The stock symbol for Geron Corporation is ""GERN.""
What Stock Exchange Does Geron Corporation Trade On?
Geron Corporation is listed and trades on the NASDAQ stock exchange.
Is Geron Corporation a Good Stock to Buy?
Determining whether Geron Corporation—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GERN quote. (ISIN: US3741631036)
1.1550
-0.1050(-8.33%)
Real-time Data·
Fair Value
An estimate of a Geron's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.1400
1.2800
52 wk Range
1.1400
4.8900
GERN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Trading near 52-week Low
More Info
Fair Value
An estimate of a Geron's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.14001.2800
52 wk Range
1.14004.8900
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GERN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Geron's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
3.3889
Upside
+193.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
- Geron Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Geron Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Geron showcases RYTELO benefits at oncology meetings
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Geron Corporation Company Profile
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation SWOT Analysis
Promising Pipeline | Explore Geron's lead drug candidate, Rytelo, showing consistent efficacy in treating myelodysplastic syndromes and potential for broader applications |
Financial Crossroads | Delve into Geron's financial landscape, balancing strong liquidity with profitability challenges as it navigates towards a projected break-even point |
Market Momentum | Analyst price targets range from $4 to $9, reflecting optimism about Geron's growth potential despite recent stock volatility |
Strategic Expansion | Learn how EU approval could be a game-changer for Geron, potentially doubling its addressable market and enhancing its global pharmaceutical presence |
Geron Corporation Earnings Call Summary for Q1/2025
- Q1 2025 EPS met forecast at -$0.03, but revenue missed at $39.6M vs $50.46M expected; stock fell 7.04% premarket to $1.27
- RYTELLO demand grew 10% in April; company expanding commercial team to boost market penetration
- Cash and equivalents at $457.5M, down from $502.9M end of 2024; operating expenses projected $270-$285M for fiscal 2025
- European launch planned by 2026; interim analysis for IMPACT MF trial in H2 2026; analysts project 83% revenue growth this year
- Management emphasized RYTELLO launch success as top priority; addressing revenue shortfall and competitive challenges
Last Updated: 07/05/2025, 14:14
Read Full TranscriptCompare GERN to Peers and Sector
Metrics to compare | GERN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGERNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.3x | −2.4x | −0.5x | |
PEG Ratio | −0.14 | 0.00 | 0.00 | |
Price/Book | 2.8x | 6.1x | 2.6x | |
Price / LTM Sales | 6.3x | 9.3x | 3.2x | |
Upside (Analyst Target) | 240.5% | 118.1% | 41.6% | |
Fair Value Upside | Unlock | 9.0% | 6.0% | Unlock |
Analyst Ratings
6 Buy
3 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 3.3889
(+193.41% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
-0.03 / -0.03
Revenue / Forecast
39.60M / 50.46M
People Also Watch
FAQ
What Stock Exchange Does Geron Trade On?
Geron is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Geron?
The stock symbol for Geron is "GERN."
What Is the Geron Market Cap?
As of today, Geron market cap is 742.01M.
What Is Geron's Earnings Per Share (TTM)?
The Geron EPS (TTM) is -0.21.
When Is the Next Geron Earnings Date?
Geron will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is GERN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Geron Stock Split?
Geron has split 0 times.
How Many Employees Does Geron Have?
Geron has 229 employees.
What is the current trading status of Geron (GERN)?
As of 28 Jul 2025, Geron (GERN) is trading at a price of 1.16, with a previous close of 1.26. The stock has fluctuated within a day range of 1.14 to 1.28, while its 52-week range spans from 1.14 to 4.89.
What Is Geron (GERN) Price Target According to Analysts?
The average 12-month price target for Geron is USD3.38889, with a high estimate of USD6 and a low estimate of USD1. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +193.41% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.